
Opinion|Videos|March 13, 2025
TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)
Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress, as well as the safety and efficacy data from the SunRISe-1 trial.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- SunRISe-1 is a phase 2b study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress. Discuss patient demographics and SunRISe-1 clinical trial design.
- Discuss the safety and efficacy data from the SunRISe-1 trial.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
TRT myths, metabolic risk, and the role of the urologist
3
How sex influences the bladder cancer tumor microenvironment
4
John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy
5



















